Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Republican senators John Cornyn and Chuck Grassley and Democratic Sen. Amy Klobuchar are rolling out a bipartisan measure to protect sensitive genetic data in response to privacy concerns sparked by ...

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...

In the latest episode of Touching Base, we discuss big news in CRISPR along with updates in the business side of biotech.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Before, we told you to delete your data because 23andMe was about to be sold. Now, a buyer has been announced, and they’re ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never ...

The backup bidder to Regeneron is a nonprofit apparently started by former 23andMe CEO Anne Wojcicki. Meet the company that ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...